
|Videos|June 19, 2023
Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials
Author(s)Alicia K. Morgans, MD, MPH
Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































